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The intramembrane proteases Signal peptide peptidase-like-2a/b (SPPL) liberate intracellular domains (ICDs) 
from type II transmembrane proteins. We describe a cell-based assay employing β-galactosidase fragment 
complementation for quantifying activity of SPPL2 or other intramembrane proteases based on detecting nuclear 
translocation of released substrate ICDs. In this system we demonstrate nuclear translocation of CD74-, TNF- 
and ITM2B-ICDs and characterize SFRP2 as potential transcriptional target of the CD74-ICD. The assay will 
allow to screen for novel inhibitors and to analyze the regulation of intramembrane proteases. 
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Abstract 
During Regulated Intramembrane Proteolysis 
(RIP) a membrane-spanning substrate protein is 
cleaved by an ectodomain sheddase and an 
intramembrane cleaving protease. A 
cytoplasmic intracellular domain (ICD) is 
liberated, that can migrate to the nucleus 
thereby influencing transcriptional regulation. 
Signal peptide peptidase-like (SPPL) 2a and 2b 
have been implicated in RIP of type II 
transmembrane proteins. Even though SPPL2a 
might represent a potential pharmacological 
target for treatment of B cell-mediated 
autoimmunity, no specific and potent inhibitors 
for this enzyme are currently available. We 
report here on the first quantitative cell-based 
assay for measurement of SPPL2a/b activity. 
Demonstrating the failure of standard Gal4/VP16 
reporter assays for SPPL2a/b analysis, we have 
devised a novel system employing 
β-galactosidase (βGal) complementation. This is 
based on detecting nuclear translocation of the 
proteolytically released substrate ICDs which 
results in specific restoration of βGal activity. 
Utilizing this potentially high-throughput 
compatible new setup, we demonstrate nuclear 
translocation of the ICDs from ITM2B, TNF and 
CD74 and identify SFRP2 as potential 
transcriptional downstream target of the CD74 
ICD. We show that the presented assay is easily 
adaptable to other intramembrane proteases and 
therefore represents a valuable tool for the 
functional analysis and development of new 
inhibitors of this class of enzymes. 
 
Intramembrane proteolysis involves the processing 
of membrane-spanning substrate proteins within 
their hydrophobic transmembrane segments by so-
called I-CLIPs (intramembrane cleaving  
proteases) (1). Usually, this process is part of a 
proteolytic cascade which is initiated by processing 
of the substrate’s ectodomain and thereby is 
involved in the turnover of a variety of membrane 




generated by intramembrane proteolysis can be 
actively involved in cellular signal transduction after 
their release from the membrane involving 
translocation to the nucleus as it is the case in 
Notch signaling (2,3). 
The SPP/SPPL family of aspartyl I-CLIPs is 
constituted by Signal peptide peptidase (SPP) and 
four homologous SPP-like (SPPL) proteins SPPL2a, 
-b, -c and SPPL3 which differ in their subcellular 
localizations (4,5). SPP/SPPL proteases show 
selectivity for substrate proteins in type 2 orientation 
and exhibit a catalytic center similar to that of the 
presenilins which are the catalytically active part of 
the γ-secretase complex. The family member 
SPPL2a is primarily localized in membranes of 
lysosomes and late endosomes (6) and was shown 
to cleave N-terminal fragments (NTF) of Tumor 
necrosis factor (TNF) (7,8), Fas ligand (9), ITM2B 
(10) and TMEM106B (11) in cell-based set-ups. So 
far, the invariant chain (CD74), a chaperone of the 
MHCII complex, represents the only in vivo 
validated substrate of this protease (12-14). CD74 
binds MHCII in the ER and facilitates targeting of 
the complex to endosomal compartments where 
CD74 undergoes step-wise proteolytic degradation 
starting from the luminal domain (15). In 
B lymphocytes of SPPL2a-deficient mice, significant 
amounts of uncleaved CD74 NTF accumulate and 
disturb homeostasis of these cells. This leads to a 
block of B cell maturation at the transitional stage 1 
(T1), a loss of dendritic cells and severely impaired 
humoral immune responses in Sppl2a-/- mice (12-
14). Though this phenotype is clearly driven by the 
CD74 NTF as documented by its alleviation in 
Sppl2a-/- Cd74-/- mice (12), the fate and putative 
downstream function of the CD74 intracellular 
domain (ICD) that is released by SPPL2a is 
insufficiently resolved. In contrast to SPPL2a, 
SPPL2b was reported to reside primarily at the 
plasma membrane (5,6). Although the substrate 
spectra of SPPL2a and SPPL2b were found to 
overlap significantly in cell-based systems, SPPL2b 
was described to be dispensable for CD74 
proteolysis under endogenous conditions indicating 
that both proteases exhibit distinct functions in vivo 
(5). 
Based on the described immunological 
phenotype of Sppl2a-/- mice (12), pharmacological 
inhibition of SPPL2a activity has been proposed as 
a strategy for depleting and/or inhibiting B cells and 
dendritic cells in a therapeutic context. Depletion of 
B cells has been shown to be beneficial in a variety 
of autoimmune disorders including systemic lupus 
erythematosus and is currently achieved with 
antibody-based therapeutics (16). Thus, a small 
molecule-based approach utilizing SPPL2a 
inhibitors would exhibit significant advantages. As 
expected from the catalytic center homology, 
several γ-secretase inhibitors, like inhibitor X, also 
target SPP/SPPL proteases. To date, (Z-LL)2-
ketone represents the only SPP/SPPL inhibitor that 
spares γ-secretase activity but acts unselectively on 
several members of the SPP/SPPL protease family 
(4). 
Since in vitro reconstitution of 
recombinantly expressed SPP/SPPL proteases as it 
is routinely employed for rhomboid I-CLIPs (17) has 
not been achieved yet, functional analysis of SPPL2 
proteases relies on cell-based systems followed by 
Western blot determination of uncleaved or cleaved 
forms of substrate proteins. Thus, a sensitive, 
quantitative and potentially high throughput-
compatible assay for monitoring activity of 
SPPL2a and other SPPL2 proteases is currently not 
available. This would, however, represent a 
prerequisite not only to further analyse the function 
and regulation of this protease but also to search for 
novel inhibitors and to optimize the available 
compounds. 
For analysis of γ-secretase, cell-based 
reporter assays have been successfully employed, 
especially for monitoring cleavage of the amyloid 
precursor protein (APP) (18-21) and Notch1 (19,22). 
In several of these studies a reporter composed of 
the yeast DNA binding protein Gal4 and the 
transcriptional activator VP16 was fused to the 
cytosolic C-terminus of the γ-secretase 
substrates (18-20). Upon proteolytic release of the 
ICD, the Gal4/VP16 reporter induces transcription of 
a luciferase via a Gal4-dependent promotor from a 
co-transfected plasmid. Luciferase activity is 
determined luminometrically and normalized via 
activity of a co-expressed reporter enzyme. 
Here, we report on a novel cell-based 
reporter assay system for determining the activity of 
SPPL2 proteases which is also applicable to other 
I-CLIPs. We show that conventional Gal4/VP16-
based reporter systems interfere with the trafficking 
of type II-oriented SPPL substrate proteins 
preventing their use for this class of proteases. 
Therefore, the novel assay utilizes β-galactosidase 
(βgal) enzyme fragment complementation (βGEFC) 
in order to detect nuclear translocation of the 
intracellular domains (ICDs) released from the 
substrate proteins by the intramembrane cleavage. 
Using this system, we assessed the ability of the 
ICDs from individual SPPL2a and SPPL2b 
substrates for nuclear localization. With respect to 
the putative therapeutic impact of the SPPL2a 
substrate CD74, we specifically validated our 
readout system for this substrate. Furthermore, we 
provide first insights into transcriptional regulation 





Conventional Gal4/VP16-assays are not 
applicable to SPPL2a/b substrates 
Cell-based assays utilizing the Gal4/VP16 reporter 
system have been successfully applied to determine 
the activity of several I-CLIPs. We therefore tried to 
expand this system to SPPL2 substrates. For this 
purpose, murine TNF, a substrate of SPPL2a, was 
tagged at its cytoplasmic N-terminus with the 
Gal4/VP16 reporter and then transiently expressed 
in HeLa cells to verify the subcellular localisation of 
this construct by indirect immunofluorescence 
(Figure 1A). In comparison to a protein carrying an 
HA epitope tag in the same position, the Gal4/VP16-
TNF fusion protein demonstrated a significantly 
altered subcellular distribution and was 
predominantly trapped in perinuclear structures not 
co-localizing with any organelles as demonstrated 




1A). Presumably, these structures represent 
aggregates of misfolded proteins. In addition to this, 
Western Blot analysis revealed rather low 
expression of the Gal4/VP16-tagged TNF in 
comparison to the HA-tagged protein (Figure 1B) 
and only very minor amounts of the TNF NTF which 
is generated by ectodomain shedding and 
represents the actual SPPL2a substrate were 
detected. Furthermore, no decrease of the TNF NTF 
levels was observed after co-expression of active 
SPPL2a. This was in sharp contrast to the HA-
tagged TNF NTF, which was clearly processed by 
SPPL2a (Figure 1B) what could be blocked by 
application of the SPP/SPPL inhibitor X.  
Nevertheless, we tried to employ the 
Gal4/VP16-tagged TNF reporter construct for a 
luciferase based SPPL activity assay and 
transfected this construct and a corresponding 
reporter plasmid into HeLa cells (Figure 1C). 
Despite the disturbed trafficking and poor 
expression of the fusion protein, transfection of this 
construct was associated with a significant increase 
of the Firefly/Renilla luciferase ratio as compared to 
vector-transfected control cells. However, this ratio 
could not be modulated by application of the 
SPP/SPPL inhibitor X. This strongly indicates that 
the luciferase expression induced by the Gal4/VP16 
TNF reporter construct was not related to SPPL-
mediated intramembrane proteolysis, but rather to 
unrelated processes like the ERAD pathway. 
 
Large cytosolic tags interfere with correct 
sorting of SPPL2a/b substrates 
Since TNF could be expressed with small N-terminal 
tags like the HA epitope but not with the large 
Gal4/VP16 tag, which comprise 9 and ~230 amino 
acids, respectively, we wondered whether the size 
of a cytosolically fused reporter might also critically 
influence expression and subcellular sorting of other 
SPPL2a/b substrates. For this purpose we 
compared processing and trafficking of CD74 
devoid of any N-terminal tag (CD74-HA) with a 
GFP-CD74 fusion protein (Figure 1D) since GFP is 
of a similar size as the Gal4/VP16 reporter. A major 
function of CD74 is to mediate trafficking of MHC II 
complexes to antigen-processing endosomal 
compartments, where CD74 is subjected to 
proteolytic degradation starting from its C-terminal 
luminal domain (15). As expected, CD74 was 
localized primarily in vesicular compartments after 
heterologous expression in HeLa cells. However, 
under the same conditions GFP-CD74 was 
predominantly retained in the endoplasmic reticulum 
as revealed by co-localization with PDI (Figure 1D). 
Correspondingly, SPPL2a-mediated processing of 
the NTFs that were produced from the GFP-tagged 
variant was not observed. In contrast, upon 
expression of CD74-HA (Figure 1E) full-length 
protein and different C-terminally truncated 
degradation intermediates were detected under 
steady-state conditions. As we showed previously 
(5,12), co-expression of SPPL2a significantly 
reduced the CD74 NTF (Figure 1E). Thus, both 
tested type II-oriented SPPL2a/b substrates TNF 
and CD74 do not tolerate larger tags at their short 
cytosolic termini in order to allow trafficking to the 
plasma membrane or the endocytic pathway which 
is a prerequisite for their proteolytic processing. 
 
The βGal α-tag is compatible with correct 
sorting and processing of SPPL2a/b 
substrates 
Since these findings precluded the use of 
Gal4/VP16 based reporter assays for the analysis of 
SPPL2a/b dependent proteolysis we considered 
alternative approaches. Therefore, we sought for a 
reporter system that would only require the addition 
of a short tag to the N-terminus of the substrate 
protein which was tolerated by CD74 and TNF 
(Figure 1) and also other substrates like TMEM106B 
(11) and ITM2B (10). This essential selection 
criterion was fulfilled by β-galactosidase enzyme 
fragment complementation (βGEFC) (23,24). 
We therefore devised the system illustrated 
in Figure 2A in order to measure the proteolytic 
activity of SPPL2 proteases based on determining 
the nuclear translocation of the released substrate 
ICDs. To achieve this, we aimed to express the 
large βGal ω-fragment, that is on its own 
catalytically inactive, in the nucleus of a reporter cell 
line. The complementing βGal α-peptide, that has a 
limited size of only ≈50 aa and is required to restore 
enzymatic activity, would then be fused to the 
N-terminus of CD74 or other SPPL2a/b substrate 
proteins. Then, βGal activity reconstitution could 
only occur after proteolytic liberation and nuclear 
translocation of the ICD.  
To test if the βGal α-tag would be 
compatible with trafficking and proteolysis of CD74, 
we created an N-terminally α-tagged CD74 
construct (α-CD74) (Figure 2B). For the case that 
the CD74 ICD generated by SPPL2a would not 
intrinsically localize to the nucleus, we generated a 
second construct harboring an SV40 NLS sequence 
(α-NLS-CD74) between the α-tag and the CD74 
N-terminus (Figure 2B). We analyzed trafficking and 
proteolytic processing of these CD74 fusion proteins 
in comparison to wild type CD74 by indirect 
immunofluorescence (Figure 2C) and Western 
blotting (Figure 2D,E), respectively. Neither 
targeting to endosomal/lysosomal compartments 
nor processing by SPPL2a was altered by the 
described tags. The latter applied to co-expressed 
(Figure 2D) as well as endogenous SPPL proteases 
(Figure 2E) as revealed by the NTF stabilization 
induced by the SPP/SPPL inhibitors (Z-LL)2-ketone 
and inhibitor X. These findings strongly support the 
applicability of βGEFC to monitor intramembrane 
cleavage of CD74. 
 
βGEFC can be employed to detect nuclear 
localisation 
Based on a previous report (25), we generated a 
reporter construct (ωnuc) of the βGal ω-fragment 
fused C-terminally to three SV40 nuclear 
localization sequences (NLS), a nuclear retention 
sequence from SC35 (NRS) and an additional NLS 
from c-Myc (Figure 3A). Using this construct, we 
produced a stable HEK293T ωnuc reporter cell line 
that showed homogenous nuclear expression of the 
ω-fragment (Figure 3A). As a positive control for the 
devised assay, we employed a GFP carrying the 
βGal α-tag in addition to three NLS at its N-terminus 
(α-eGFPnuc) in order to facilitate constitutive 
transport of the expressed protein to the nucleus 




(Figure 3B). In contrast, TMEM192 is a multi-
spanning integral protein of the lysosomal 
membrane (26,27) for which proteolytic cleavage 
has not been observed, thus precluding that the 
N-terminally fused α-tag reaches the ω-reporter in 
the nucleus (Figure 3C). The α-eGFPnuc and 
α-TMEM192 control constructs were transiently 
expressed in the ωnuc-reporter cell line and βGal 
activity was determined using a luminescent 
substrate (Figure 3D). In order to account for 
differences in transfection efficiency, the βGal 
activity was normalized to the activity of a co-
expressed firefly luciferase. Whereas significant 
βGal activity was detected in cells expressing the 
nuclear-localized α-eGFPnuc, almost no βGal 
reconstitution was observed following expression of 
α-TMEM192. This confirms suitability of the 
described system to determine nuclear translocation 
of α-tagged proteins. 
 
The CD74 ICD is capable of nuclear 
translocation 
To verify the applicability of the developed βGEFC 
based assay system we focused on CD74 as model 
substrate. Therefore we first transfected the α-CD74 
and α-NLS-CD74 constructs described in Figure 2 
into the ωnuc reporter cell line and analyzed the cells 
for βGal complementation. Upon application of 
these constructs to our βGal assay system, we 
observed a normalized βGal activity that was 
significantly higher than that of the negative control 
α-TMEM192 (Figure 4A). This detected βGal activity 
indicated a translocation of the CD74 ICD to the 
nucleus following its processing. This effect was 
further enhanced by an additional NLS sequence. 
Nevertheless, these data strongly indicate the 
capability of the α-tagged CD74 ICD to translocate 
to the nucleus upon its generation by SPPL2a. We 
also confirmed dose dependency of the βGal activity 
resulting from transfection of α-CD74 (Figure 4B).  
In the following, we focused on the  
α-tagged CD74 wild type construct (α-CD74) to 
validate that the βGal reconstitution following 
expression of this construct was indeed dependent 
on intramembrane proteolysis by SPPL2a that 
precedes nuclear translocation of the CD74 
N-terminus. Therefore, we co-expressed α-CD74 
with SPPL2a and observed that presence of the 
protease significantly augmented βGal activity 
(Figure 4C) indicating increased levels of CD74 ICD 
in the nucleus in the presence of SPPL2a. This 
effect was reversed when activity of SPPL2a was 
blocked by concomitant inhibitor X application, an 
inhibitor of SPP/SPPL proteases and γ-secretase. 
These findings are in agreement with observations 
from Western blot analysis (Figure 2D), where co-
expression of SPPL2a enhanced turnover of CD74 
NTF. 
We also investigated processing of  
α-tagged CD74 by endogenous proteases in this 
system using inhibitor treatment (Figure 4D). The 
SPPL2a inhibitors (Z-LL)2-ketone and inhibitor X 
significantly reduced α-CD74 associated βGal 
reconstitution. Processing of the CD74 luminal 
domain represents a prerequisite of CD74 
intramembrane cleavage by SPPL2a (12) since only 
the NTF and not the full-length protein is a substrate 
of the protease. We evaluated the effect of 
preventing lysosomal/endosomal acidification by 
bafilomycin A1 and of endosomal protease inhibition 
by E64 or leupeptin on CD74 ICD generation in the 
βGal system. Both approaches are known to inhibit 
CD74 degradation (28,29). Here, all three 
compounds reduced the detected normalized βGal 
activity in α-CD74 expressing cells versus solvent-
treated controls indicating that upon interference 
with CD74 ectodomain proteolysis less CD74 ICD is 
produced. This agrees well with the observation that 
co-expressed SPPL2a does not modulate the full-
length form of CD74, but only a truncated NTF 
(Figure 2D) as shown by Western blotting. Since  
(Z-LL)2-ketone and inhibitor X are active against 
several members of the SPP/SPPL protease family, 
we sought to confirm the role of endogenous 
SPPL2a for CD74 ICD release in our βGal reporter 
cell line by knockdown of SPPL2a. In cells treated 
with SPPL2a versus non-targeting control siRNA 
(Figure 4E), normalized βGal reporter activity 
following α-CD74 transfection was reduced to a 
similar degree as by treatment with (Z-LL)2-ketone 
or inhibitor X (Figure 4D). This result validates the 




The CD74 ICD is degraded by the 
proteasome 
We wanted to elucidate the pathways involved in 
turnover of this proteolytic fragment following its 
release by SPPL2a. Therefore, we treated α-CD74 
transfected ωnuc cells with the proteasome inhibitors 
epoxomicin and bortezomib or a mixture of 
amastatin, bestatin and AAF-CMK, all inhibitors of 
cytosolic peptidases. Incubation with the 
proteasome inhibitors led to a significant increase in 
normalized βGal activity, whereas treatment with the 
peptidase inhibitor did not show any significant 
effect under these conditions (Figure 5A). We 
scrutinized if the observed effect upon proteosomal 
inhibition indeed reflected stabilization of the CD74 
ICD generated by SPPL2a-mediated 
intramembrane cleavage. Therefore, we treated the 
cells with inhibitor X for 2 h before and also during 
epoxomicin application. The interference with CD74 
processing resulted in a significant, however not 
complete, rescue of the epoxomicin dependent 
increase in βGal reconstitution (Figure 5B). 
Furthermore, we excluded by Western blot analysis 
that significant stabilization of the βGal ωnuc reporter 
had been induced by the applied proteasomal 
inhibitors (Figure 5C). Though this does not rule out 
additional stabilising effects of the proteasome 
inhibitor on CD74 fragments generated by putative 
SPPL2a-independent mechanisms such as ER-
associated degradation (ERAD) due to 
overexpression, these results nonetheless indicate 
a major role of the proteasome in the degradation of 
the CD74 ICD. 
 
A potential role of the CD74 ICD in 
transcriptional regulation 
After having documented the capability of the 
α-CD74 ICD to translocate to the nucleus, we 
sought to investigate any putative impact of the 




overexpression of the CD74 ICD has not been 
successful in our hands, presumably due to its small 
size, we devised the system depicted in Figure 5D 
for controlled overexpression of the CD74 ICD 
mimicking its proteolytic release from a 
transmembrane precursor. In the generated 
constructs (Figure 5D), the 35 N-terminal residues 
of murine CD74 (ICD) were fused to eGFP followed 
by the transmembrane segment of human 
syntaxin 7 anchoring the fusion protein to the 
membrane. Between the CD74 ICD and the eGFP, 
a linker was inserted containing either a cleavage 
site (ENLYFQG) for the NIa protease from the 
tobacco etch virus (TEV protease) or a stretch of 
alanines (± TEV site). In both constructs, TEV 
protease is co-expressed from the same plasmid 
employing an internal ribosome entry site (IRES) 
mediating release of the CD74 ICD specifically from 
the fusion protein with the TEV cleavage site 
whereas the CD74 ICD remains membrane-bound 
in the control. Since the TEV protease is highly 
specific, heterologous expression of this protease is 
well tolerated in different experimental systems, 
including mammalian cells (30).  
We generated stable HEK293 cells 
inducibly expressing both constructs and validated 
their functionality regarding membrane localization 
of the CD74 ICD-GFP fusion proteins (not shown) 
and the proteolytic processing upon presence of the 
TEV cleavage site (Figure 5E). Interestingly, the 
released CD74 ICD was not directly observed (not 
shown) despite its confirmed production indicating 
that intrinsic properties of this fragment impede its 
Western blot-based detection. We determined and 
compared genome wide transcriptome profiles of 
both cell lines. In order to detect changes in gene 
expression patterns induced by the proteolytically 
released CD74 ICD, we calculated fold changes 
between the cell line expressing the cleavable CD74 
ICD fusion protein versus the control cell line where 
the ICD is not liberated. Transcripts that appeared 
differentially expressed more than two-fold between 
the two cell lines are listed in Suppl. Table S1. 
Among these were ten protein-coding transcripts, 
from which four appeared to be up- and six down-
regulated. We did not further analyze OR514A, 
TASR30 and KRTAP9-1 due to their very specific 
roles as olfactory and taste receptors or in hair 
follicles, respectively. In contrast, the suggested 
differential expression of TULP3, ZNF763, SFRP2, 
DHRSX, LUM, TPTE and CNTN1 was re-evaluated 
by quantitative RT-PCR (Suppl. Figure S1). In this 
analysis, ZNF763 mRNA was not detected and no 
difference was found for TPTE, TULP3 and DHRSX. 
However, CD74 ICD-associated upregulation of 
SFRP2 (Figure 5F) as well the reduction of CNTN1 
and LUM expression was confirmed.  
We asked if this effect of the 
overexpressed CD74 ICD could also be relevant 
under endogenous conditions. Sfrp2 mRNA has 
been detected in bone marrow-derived dendritic 
cells (BMDC) by transcriptomic profiling (31). Since 
dendritic cells abundantly express endogenous 
CD74, we analyzed consequences of a reduced 
ICD generation in BMDCs. Therefore, we compared 
Sfrp2 transcript levels in Sppl2a-/- and Cd74-/- 
BMDCs, in which generation of the CD74 ICD 
cannot occur due to the absence of either the 
protease or the substrate, to BMDCs isolated from 
wild type mice (Figure 5G). SFRP2 expression was 
significantly down-regulated in both the SPPL2a- 
and the CD74-deficient cells. This agrees well to the 
described increase of SFRP2 expression upon 
CD74 ICD overexpression. In conclusion, these 
findings strongly indicate that the CD74 ICD can 
have a regulatory impact on gene expression also 
under endogenous conditions advocating further 
investigations especially regarding the underlying 
mechanism. 
 
Nuclear translocation of ICDs from other 
SPPL2a/b substrates 
Following the corroboration of the βGal assay 
system to monitor intramembrane cleavage of CD74 
proteolysis, we sought to evaluate its applicability to 
other substrates of SPPL proteases. Therefore, we 
created N-terminally α-tagged expression constructs 
of TNF and ITM2B (Figure 6A) with or without an 
inserted additional NLS sequence. We analyzed the 
subcellular distribution of these α-tagged proteins in 
comparison to the wild type proteins with an 
N-terminal HA tag (Figure 6B). In analogy to CD74, 
we did not detect any impact of the α-tag on 
intracellular trafficking of TNF and ITM2B. Both 
constructs were able to reach the cell surface. 
Expression of the generated TNF and ITM2B 
constructs (α-TNF, α-ITM2B) resulted in normalized 
βGal activities that were significantly higher than 
those provoked by the negative control α-TMEM192 
(Figure 6C). Similar to CD74, βGal reconstitution 
was enhanced by an additional NLS in the TNF and 
ITM2B reporter constructs (α-NLS-TNF, α-NLS-
ITM2B). 
We aimed to confirm that the α-TNF and 
α-ITM2B induced assay signals were dependent on 
intramembrane cleavage by SPPL2a and/or 
SPPL2b. Therefore, we co-expressed α-TNF and  
α-ITM2B with both proteases (Figure 6D,E) and 
observed enhanced α-TNF and α-ITM2B associated 
βGal reconstitution what could be partially blocked 
by concomitant application of inhibitor X. In 
conclusion, these results show that the described 
assay can also be employed to determine the 
turnover of other substrates than CD74 by SPPL 
proteases. Furthermore, our findings demonstrate 
that in this system SPPL2a/b-generated TNF and 
ITM2B ICDs are able to translocate to the nucleus. 
While this has been suggested before for the TNF 
ICD (7,32), a capability of the ITM2B ICD to access 
the nucleus has not been reported previously 
according to our knowledge. 
 
The βGal reporter assay can be adapted to 
other intramembrane proteases 
Finally, we wanted to assess if the described βGal 
reporter assay system can be adapted to substrate 
proteins of different topology and/or of other than 
SPPL intramembrane proteases. To investigate this, 
we chose the type 1 transmembrane protein Notch 
as one of the best studied substrates of 
intramembrane proteolysis (3). Ligand binding 
induces proteolytic shedding of the Notch 
ectodomain that is followed by γ-secretase 
processing of the remaining C-terminal stub 




the ICD (3). We used a Notch expression construct 
devoid of the ectodomain (NotchΔE) (Figure 7A) 
(33). Therefore, upon expression in HeLa cells this 
truncated Notch protein was constitutively 
processed by γ-secretase and the released 
C-terminal ICD could be detected in the nucleus 
(Figure 7B). Upon inhibition of γ-secretase by 
DAPT, generation of the ICD was prevented so that 
the NotchΔE protein remained membrane-
associated (Figure 7B). With respect to applicability 
in our reporter assay, the employed NotchΔE 
construct carried the βGal α-tag at its cytosolic 
C-terminus. In the ωnuc reporter cell line, expression 
of the NotchΔE-α construct restored βGal activity to 
about 70% of the level observed with the positive 
control α-eGFPnuc (Figure 7C). Upon concomitant 
γ-secretase inhibition by DAPT, significantly less 
βGal activity was measured. This effect was not 
observed with the SPP/SPPL inhibitor (Z-LL)2-
ketone. Thus, the established βGal reporter assay 
can be employed to monitor γ-secretase mediated 
cleavage of Notch as well as the nuclear 
translocation of the Notch ICD. This finding 
substantiates applicability of the system to monitor 
proteolysis of different substrate topologies as well 




In this study, we sought to create a cell-based 
reporter assay to monitor the activity of the 
intramembrane proteases SPPL2a and SPPL2b in 
order to provide an alternative to cumbersome 
Western blot procedure when studying these 
enzymes. To achieve this, we failed to adapt the 
Gal4/VP16 reporter system that has been 
successfully applied to monitor cleavage by 
γ-secretase (18-22) or the ER protease 
SPP (34,35). Apparently, in these studies the 
cleavage of type 1 transmembrane proteins or ER 
proteins in type 2 orientation was analyzed. Here, 
we showed that N-terminal fusion of the Gal4/VP16 
reporter, that comprises about 230 amino acids, or a 
protein of a similar size (GFP) was not compatible 
with regular trafficking and proteolysis of the 
SPPL2a/b substrates TNF and CD74. These 
proteins exhibit a type 2 transmembrane topology 
with a short cytoplasmic N-terminal domain (~30 
residues) and need to travel via the secretory 
pathway to the plasma membrane and/or 
endosomal compartments. In the case of CD74, 
essential sorting motifs in this N-terminal part of the 
protein have been identified (36). The Gal4/VP16-
TNF construct was expressed at very low levels as 
compared to the wild type construct suggesting, that 
in this case even folding and/or membrane insertion 
of the fusion protein in the ER were disturbed. Since 
the other currently known SPPL2a/b substrates 
ITM2B (10), Fas ligand (9), transferrin receptor (37) 
and TMEM106 (11) exhibit a similar topological 
layout to the ones examined, it can be concluded 
that the Gal4/VP16 reporter system is not suitable to 
monitor intramembrane cleavage by SPPL2a/b. 
We demonstrate here that a split reporter 
system based on βGal (βGEFC), that only requires 
the addition of a short tag to the N-terminus of the 
substrate protein, can be exploited to create a cell-
based reporter assay for SPPL2a/b-mediated 
intramembrane proteolysis. This system allowed 
quantitative detection of the ICDs following their 
release from the membrane-bound substrate 
proteins. We showed that modulation of protease 
activity in a positive or negative way by 
overexpression, knockdown or pharmacological 
inhibition, respectively, was reflected in a 
corresponding modulation of the assay signal thus 
validating this as a quantitative readout of 
SPPL2a/b-mediated proteolysis. We especially 
sought to provide an assay for the intramembrane 
cleavage of CD74 by SPPL2a based on the 
documented in vivo relevance of this process and its 
potential as a therapeutic target (12-14). However, 
we also confirmed applicability of the βGEFC-based 
assay system for other SPPL2a/b substrates like 
TNF and ITM2B and demonstrated that cleavage of 
the type 1 transmembrane protein Notch1 by 
γ-secretase could be monitored by this means. 
Thus, the βGEFC reporter assay is not restricted to 
a certain substrate topology and may be further 
extended to other classes of intramembrane 
proteases.  
Protein fragment complementation 
describes the reconstitution of a protein’s function or 
enzymatic activity from two separately synthetized 
fragments when these are brought into 
proximity (38). A variety of different split-reporter 
systems have been designed and used in multiple 
applications, especially for the analysis of protein-
protein interactions (38). Among these, a quite 
unique property of split βGal is the pronounced size 
asymmetry of the two fragments comprising ~50 (α) 
and ~950 (ω) amino acids (23) that are capable of 
reconstituting βGal activity, making it especially 
suited for the purpose of this study. We found that 
the small βGal α-peptide in contrast to other 
reporters did not interfere with trafficking and 
proteolysis of SPPL2a/b substrates. βGal-based 
readout systems have been successfully employed 
in high-throughput screening applications (39). 
Similar to other split-protein reporters, βGEFC has 
been exploited to monitor protein-protein 
interactions (40). However, due to the high affinity 
complementation of the two βGal fragments already 
their presence in the same subcellular compartment 
can be sufficient to promote assembly of a 
functional enzyme. This fact has been utilized for 
designing cell-based assays to detect nuclear 
translocation of target proteins (24,25,41), 
especially in order to provide a readout for the 
activation of certain signaling pathways, like 
Wnt (41) and glucocorticoid receptor (25) signalling. 
In the present study we have extended this 
application to monitor proteolytic processes at 
biological membranes by the proteases SPPL2a/b. 
Adaption of the described system to design assays 
for other intramembrane proteases is possible and 
may provide essential advantages over previously 
employed reporters especially for substrate proteins 
with short cytoplasmic domains. 
We demonstrated that the βGEFC assay 
system is suitable to monitor SPPL2a-mediated 
cleavage of CD74 since interference with this 
process led to a significant reduction of the assay 
signal. However, pharmacological inhibition of 




signal. Similar effects were observed upon 
knockdown of the protease which led to a 
significant, though incomplete depletion of the 
SPPL2a protein. Therefore, we hypothesize that 
also in the inhibitor-treated cells residual SPPL2a 
activity accounts for the remaining assay signal. 
This would indicate that either the affinity of the 
used compounds or their cell-permeability or a 
combination of both are limiting in order to achieve a 
full inhibition. However, we can also not exclude that 
part of the CD74-associated assay signal reflects 
SPPL2a-independent degradative routes that 
liberate CD74 proteolytic fragments into the cytosol. 
Furthermore, also minor amounts of the βGal 
ω-fragment in the cytosol, that we failed to detect 
with immunofluorescence, could in principle account 
for a SPPL2a-independent background signal. 
However, this should have also affected signals for 
the negative control α-TMEM192, which we used as 
baseline. Therefore, we consider this as unlikely. 
When studying intramembrane proteolysis, 
the fate and function of the intracellular cleavage 
products is an immanent question related to the 
technical difficulties to detect these often small, low-
abundant protein fragments biochemically. The 
latter also applies to the ICD released from CD74. 
We have been unable to detect this released CD74 
ICD by biochemical means directly in total cell 
lysates what is most likely due to its small size of 
30-40 amino acids and/or its rapid turnover. Our 
assay data (Figure 5) point to a degradation of the 
CD74 ICD by the proteasome. This pathway might 
be influenced by the putative D box motif (RXXL) in 
the cytoplasmic region of the CD74 protein (42). 
However, also concurrent inhibition of the 
proteasome (bortezomib, epoximicin) did not 
enhance biochemical detectability of this cleavage 
product by Western blotting in our hands. This may 
indicate that primarily its unfavourable properties 
impair its recovery with this technique which was not 
resolved despite significant optimization efforts. In 
this context, the described βGEFC assay system 
represents a valuable approach to examine the cell 
biological fate of the CD74 ICD. Beyond providing a 
quantitative readout for protease activity it also 
allows to explore the capability of the respective 
cleavage fragments for entering the nucleus. 
Nuclear translocation of CD74 fragments has been 
suggested before (43), however, the proteolytic 
machinery for the intramembrane cleavage of CD74 
was unknown until recently (12-14). In our βGEFC 
system, we could demonstrate that the CD74 ICD 
released by the intramembrane protease SPPL2a 
has the capability to migrate to the nucleus which 
could indicate a physiological function of this 
process similar to other I-CLIP substrates (44). 
In this regard, we demonstrated that the 
CD74 ICD may play a role in influencing 
transcriptional regulation as exemplified by the 
identification of SFRP2 as a potential target gene. In 
different cellular systems, modulation of CD74 ICD 
generation and release was reflected in 
corresponding changes of SFRP2 transcript levels. 
SFRP2 is a secretory protein that has been found to 
be a negative regulator of Wnt signaling (45,46). 
Furthermore, amongst other functions SFRP2 has 
been suggested to act as a tumor suppressor since 
it was shown to induce apoptosis and promote 
tumorigenesis (46,47). The physiological relevance 
of a regulatory circuit between CD74 and SFRP2 in 
dendritic cells as we showed here needs further 
insights. Interestingly, SFRP2 was reported to be 
secreted in pathophysiologically relevant amounts 
by multiple myeloma, a neoplasm of plasma cells 
(48). This process was demonstrated to contribute 
to the bone loss induced by these tumors via 
suppressing bone formation. At the same time, high 
expression levels of CD74 are usually observed in 
multiple myeloma (49). It may be interesting to test if 
the CD74 ICD contributes to the documented up-
regulation of SFRP2 in these neoplastic plasma 
cells. The precise molecular mechanism how the 
CD74 ICD enhances SFRP2 expression is currently 
unclear. It has been reported previously that the 
released CD74 ICD has an impact on NFκB 
signaling (42). Therefore, we analyzed our 
microarray data set for any CD74 ICD-associated 
expression modulation of established NFκB target 
genes or components of this pathway (Suppl. Table 
S2). However, we could not find any changes 
arguing for a differential activation of the NFκB 
pathway in those cells expressing the cleavable 
versus the non-cleavable CD74 ICD fusion protein. 
This was also supported by biochemical analysis of 
IκBα levels (not shown). Therefore, we did not 
obtain any evidence that in this cell system the 
effect on SFRP2 involves components of the NFκB 
pathway. We think that the overexpression system 
we have utilized to mimick proteolytic liberation of 
the CD74 ICD in combination with transcriptomic 
profiling represents a well-controlled, unbiased 
approach that will also be useful to investigate the 
effects of other ICDs released by I-CLIPs. In this 
context, we consider the current dataset merely as a 
proof-principle experiment that provides first 
indications for a regulatory role of the CD74 ICD. 
We think that our findings strongly advocates to 
adapt the system to (murine) immune cells that also 
endogenously express CD74 which would further 
enhance the validity of the approach. 
Using the βGEFC assay, we could also 
confirm nuclear translocation of the TNF ICD in line 
with previous reports (7,32). This ICD was reported 
to enhance expression of the pro-inflammatory IL12 
after its liberation by SPPL2a/b-mediated 
proteolysis (7). In contrast to TNF, the molecular 
function of the ITM2B protein is much less 
understood to date (50). This protein is genetically 
linked to the familial British and Danish forms of 
dementia and has been reported to influence 
processing of the amyloid precursor protein (51). 
However, little is known about the physiological 
relevance of the ITM2B intramembrane cleavage by 
SPPL2a/b following release of the ectodomain by 
ADAM10 (10). Here, we reveal for the first time that 
the ITM2B ICD can travel to the nucleus following its 
proteolytic liberation. This could suggest a specific 
function of the ITM2B ICD in signal transduction and 
transcriptional regulation that will need to be further 
investigated. 
Another interesting question is whether the 
relative small ICD of this protein as well as that of 
TNF and CD74 is trafficked to the nucleus by 
specific transport mechanisms. Since molecules 
with a size <40 kDa are able to enter this 




likely also applies to the small substrate ICDs. In 
general, our findings on the capability of SPPL2a/b 
substrates to localize to the nucleus are in 
agreement with findings for many of the numerous 
substrates of the related γ-secretase complex (44). 
For those substrates of γ-secretase or other 
intramembrane proteases where biochemical 
detection of the intracellular cleavage products is 
inherently difficult the described βGEFC reporter 
system will provide a powerful tool to clarify the 
cellular fates of these fragments. In addition to this, 
the assay described above will provide a versatile 
technique not only for elaborating intramembrane 
cleavage of RIP substrates but also for the 
preceding and kinetically linked shedding process 
as we could show for the luminal processing of 
CD74. Therefore, we are confident that the devised 
assay system provides a new valuable tool for the 
functional analysis of SPPL2a/b and also other 
intramembrane proteases as well as for the search 
of novel inhibitors of these enzymes. 
 
Materials and Methods 
 
Reagents 
The SPP/SPPL-inhibitors (Z-LL)2-ketone 
(Peptanova) and inhibitor X (EMD Millipore) were 
used at final concentrations of 20 µM and 1 µM, 
respectively. For selective inhibition of γ-secretase, 
DAPT (Sigma) was applied at 1 µM final 
concentration. Proteasome inhibition was performed 
with bortezomib (Selleck chemicals) and epoxomicin 
(Peptanova) at concentrations of 5 µg/ml and 1 µM, 
respectively. Amastatin (1 µM, Peptanova), bestatin 
(20 µM, Sigma) and AAF-CMK (10 µM, Peptanova) 
were used to target cytosolic peptidases. To 
interfere with processing of the CD74 luminal 
domain, leupeptin (2.5 µM, Roth), E64 (10 µM, 
Enzo) and bafilomycin A1 (300 nM, Sigma) were 
utilized as inhibitors of lysosomal proteases and 
lysosomal acidification, respectively. Except for 
AAF-CMK, leupeptin and E64 which were dissolved 
in H2O, stock solutions from all other compounds 
were prepared in DMSO (Roth) or DMSO/H2O 
mixtures. Doxycyclin (used at 10 µg/ml) was 
purchased from Sigma. 
 
Cloning and constructs 
Murine TNF was tagged with an N-terminal HA- and 
a C-terminal V5 tag and inserted into the pcDNA3.1 
hygro (+) vector backbone (Invitrogen). An 
N-terminal HA-tag was added to the open reading 
frame of murine ITM2B via PCR using extended 
primers and the fusion construct was cloned into 
pcDNA3.1 hygro (+) via its XbaI and BamHI sites. 
For generation of the Gal4/VP16-mTNF fusion 
construct the Gal4/VP16 reporter coding was 
amplified from pMst-GV (18) and fused to mTNF via 
fusion PCR. The pL8G5-Luc vector, the response 
plasmid for the Gal4/VP16 reporter, as well as the 
pMst-GV plasmid were a kind gift of Thomas Südhof 
and Jacqueline Burré. The pRL-TK vector coding for 
a Renilla Luciferase used as transfection control for 
Gal4/VP16 assays was from Promega. To 
furthermore test the applicability of large tags to the 
N-termini of SPPL2a/b substrate molecules, the p31 
isoform of murine CD74 (12) CD74 was cloned into 
pEGFP-C1 (Clontech) to fuse its coding sequence 
with the one of GFP. 
The nuclear βGal reporter construct (ωnuc) 
was cloned by deletion of the coding sequence for 
amino acids 12-42 of E. coli βGal. To achieve stable 
nuclear localization of the βGal reporter, three SV40 
nuclear localization sequences (NLS, DPKKKRKV) 
(54), the SC35 nuclear retention signal (NRS, 
PPPVSKRESKSRSRSKSPPKSPEEEGAVSSDLKV
RKAA, see (55)) and an additional NLS derived 
from the transcription factor c-Myc (DLKVRKAA) 
(56) were fused by two consecutive PCRs to the 3’ 
end of the reporter construct according to (25). The 
final PCR product was inserted via appended 
BamHI and XbaI sites into pcDNA3.1 hygro+ that 
was also used for all expression constructs 
described below. The resulting construct was 
termed ωnuc. For each SPPL substrate analyzed, 
expression constructs with the complementing βGal 
α-peptide fused to the N-terminus (α-tag) were 
generated with or without an additional SV40 NLS in 
order to facilitate nuclear translocation of the 
released ICD also in the absence of a functional 
intrinsic nuclear import motif. In a first step, either 
the α-tag alone (MSSNSLAVVLQRRDWENP 
GVTQLNRLAHPPFASWRNSEEARTDRPSQQLRS
LNGE) or in combination with an additional SV40 
NLS was appended to the 5’ end of the coding 
sequence of the p31 isoform of murine CD74 (12) 
by PCR with an BamHI site in between. The whole 
fragment was then integrated via introduced NheI 
and XbaI sites into pcDNA3.1 hygro+. For the 
generation of murine TNF and ITM2B assay 
constructs, the CD74 coding sequence was excised 
from the α-tagged CD74 constructs by restriction 
digest with BamHI and XbaI and the respective 
open reading frames were inserted in frame via 
corresponding 5’ and 3’-terminal sites added by 
PCR. A C-terminally α-tagged expression construct 
of the established γ-secretase substrate Notch1 was 
generated based on the murine NotchΔE-GFP 
construct described in (33). This was devoid of the 
Notch1 extracellular domain allowing constitutive 
cleavage by γ-secretase independent of ligand 
binding and ectodomain shedding. To enable 
detection of this construct, an HA-tag was inserted 
between the NotchΔE coding sequence and the 
βGal α-tag. As a positive control for nuclear 
localization, we fused the βGal α-tag and three 
SV40 NLS to the open reading frame of GFP (from 
peGFP-N1, Clontech) resulting in a constitutive 
nuclear transport of GFP (α-eGFPnuc). As an 
extranuclear negative control, we created an 
N-terminally α-tagged construct of the human 
lysosomal integral transmembrane protein 192 (α-
TMEM192) that we have characterized previously 
(26,27). Plasmids coding for murine SPPL2a/b and 
the inactive SPPL2a-D416A mutant have been 
described before (5,6,12). An expression construct 
of firefly luciferase in a pcDNA3 vector (57) was 
obtained from Addgene (plasmid no. 18964).  
To generate a system that allowed for 
expression of the CD74 ICD (aa 1-35) a construct 
was generated that harboured this protein fragment 
attached to a GFP and a human syntaxin 7 
membrane anchor (aa 229-261). Either a TEV 




alanines (A7) were inserted between the CD74 ICD 
and the membrane anchored GFP to allow or inhibit 
cleavage by a myc-tagged TEV protease 
coexpressed from the same plasmid via an IRES 
sequence. While the CD74 ICD coding sequence 
was amplified from plasmids described above, the 
nucleotide sequences corresponding to GFP was 
amplified from pEGFP-N1 (Clontech). The coding 
sequence of the human syntaxin7 membrane 
anchor as well as the TEV protease cleavage site or 
the A7 stretch were attached by consecutive PCRs 
using extended primers. IRES sequence and the 
TEV protease open reading frame were amplified 
from pIRES2-EGFP (Clontech) or pRK1043 
(Addgene 8835), respectively. Finally, the 
sequences were joined by overlap-extension PCRs 
and cloned into pcDNA5.1/FRT/TO (Life 
Technologies) via its BamHI and XhoI sites. The 
constructs were termed CD74 ICD-TEV-GFPmem or 
CD74-ICD-A7-GFPmem, respectively. 
 
Cell culture and transfection 
HeLa (DSMZ) and HEK293T cells were maintained 
in DMEM (Sigma) supplemented with 10% fetal 
bovine serum (Biochrom) as well as 100 U/ml 
penicillin (Sigma) and 100 µg/ml Streptomycin 
(Sigma). Cells were cultivated at 37°C in a 
humidified 5% CO2/95% air atmosphere. All 
transfections of plasmid DNA were performed with 
Turbofect (Thermo Scientific) according to 
manufacturer’s instructions.  
A reporter cell line stably expressing ωnuc 
was generated by transfection of HEK293T cells 
with the corresponding plasmid and subsequent 
selection of positive clones with 250 µg/ml 
hygromycin (Invivogen). After subcloning, individual 
clones were evaluated regarding homogeneity of 
expression and nuclear localization of the reporter 
construct as determined by indirect 
immunofluorescence as well as discrimination 
between positive and negative control under assay 
conditions. The best-performing cell line according 
to these criteria was chosen for further experiments 
and termed ωnuc.  
To generate a cell line that would allow for 
the inducible expression of the CD74 ICD, the 
FlipIn™T-Rex™293 cell line (Life Technologies) 
was transfected with either the CD74 ICD-TEV-
GFPmem or CD74-ICD-A7-GFPmem construct and the 
pOG44 vector (Life Technologies). Subsequently, 
cells were selected with 100 µg/ml hygromycin and 
10 µg/ml blasticidin (Invivogen). Since the FlipIn™ 
system facilitates site-directed integration of the 
transfected constructs and transgene expression in 
the selected cells was homogenous as determined 
by indirect immunofluorescence, cells were 
maintained as a batch without subcloning. In the 
following, these CD74 ICD-TEV-GFPmem or CD74 
ICD-A7-GFPmem cell lines were used for microarray 
and qRT-PCR analysis. 
For knock-down of SPPL2A in the 
HEK293T reporter cell line, a pool of four gene-
specific siRNAs (SMARTpool: GUUGUUGCCUGGA 
GACGUA, GGAGUGGACUAGUUGAAUU, 
CCUCAUGCCUGUUUCAAUA, GGUAACAGCUA 
UCAGAUGA) as well as of non-targeting siRNAs 
(pool #1) were obtained from Thermo Scientific and 
transfected using INTERFERin (Polyplus 
transfection) following the supplier’s 
recommendations. A final concentration of 20 nM 
siRNA in the culture medium was used for efficient 
knockdown of SPPL2A. siRNA transfection was 
directly performed at the time of cell seeding and 
repeated after 48 h incubation.  
 
Gal4/VP16-transactivation assays 
HeLa cells (5x104) were seeded in 24-well-plates 
and transfected with pRL-TK, pL8G5-Luc and empty 
vector or Gal4/VP16-TNF as indicated. On the next 
day, the cells were treated with 1 µM inhibitor X or 
the corresponding amount of DMSO for 6 h and 
lysed by applying Passive lysis buffer (Promega). 
Afterwards, 20 µl of the uncleared lysate were 
analyzed for luciferase activity using the Dual-
Luciferase® Reporter Assay System kit (Promega) 
according to the manufacturer’s instructions. 
Luminescent signals were detected using a 
GloMax™ 96 well plate luminometer (Promega) 
applying a two-injections-protocol. For evaluation of 
the experiments, the determined Firefly luciferase 
activity was divided by the corresponding Renilla 
activity for each sample. This Firefly/Renilla 
luciferase signal ratio was then normalized to that 




βGEFC assay procedure 
For βGal enzyme fragment complementation 
assays, 104 cells of the ωnuc reporter cell line were 
seeded in 100 µl medium without hygromycin in 96 
well plates (Greiner Bio-One) suitable for 
luminescence assays. On the following day, cells 
were transfected with α-tagged substrate or control 
constructs as well as firefly luciferase to allow 
normalization of transfection efficiency. After one 
day of culture post transfection, cells were either 
used directly for luminescent determination of βGal 
and luciferase activities or following a 6 h treatment 
with inhibitors as indicated. Activities of the reporter 
enzymes were measured employing the Dual-
Light® Luciferase & β-Galactosidase Reporter Gene 
Assay System (Life technologies) and a GloMaxTM 
96 well plate luminometer E6521 (Promega). 
Measurements were performed at least in technical 
duplicates based on two independent transfections. 
For evaluation, βGal/firefly luciferase (βGal/Luc) 
activity ratios were calculated for each individual 
sample. These ratios were normalized as indicated 
either to positive control samples (α-eGFPnuc) that 
were part of each assay or, when protease activity 
was modulated, to solvent treated or mock 
transfected samples. In both cases, the individual 
sample ratios were divided by the mean value of the 
respective control samples that were used as basis 
for the normalization. Figures show mean values 
and SEM of at least three independent experiments 
each carried out with at least two technical 
duplicates per condition. 
 
Western blotting 
Protein was extracted from harvested cells as 
described previously (26). Protein concentration of 
total lysates was determined with a BCA protein 
assay (bicinchoninic acid, Thermo Scientific). 




with tris-glycine (58) or tris-tricine (59) buffer 
systems as applicable, semi-dry transfer of protein 
to nitrocellulose membranes was performed as 
reported in (26). For immunodetection of murine 
CD74, the established monoclonal antibody In-1 
directed against the CD74 intracellular domain was 
employed (BD Biosciences). To detect cleavage 
fragments of TNF a rabbit polyclonal antibody was 
generated against a synthetic peptide 
corresponding to aa 4-22 of murine TNF 
(ESMIRDVELAEEALPQKMG). A rabbit monoclonal 
anti-GFP antibody was obtained from Cell signaling. 
The monoclonal 3F10 antibody recognizing the 
Hemagglutinin (HA) epitope and the monoclonal 
9B11 antibody against the Myc epitope were 
purchased from Roche and Cell Signaling, 
respectively. The generation of antibodies against 
murine and human SPPL2a has been reported 
before (6,60). Expression of the βGal ω-fragment 
was detected using an anti-βGal-antibody 
(Promega). To confirm equal protein loading, a 
rabbit polyclonal antibody against β-Actin (Sigma) 
was used. HRP-conjugated secondary antibodies 
for chemiluminescent detection were from Dianova. 
 
Indirect immunofluorescence 
For indirect immunofluorescence analysis, 5x104 
HeLa cells were seeded out on coverslips in 12 well 
plates the day before transfection. One day post 
transfection cells were fixed with 4% (w/v) 
paraformaldehyde and permeabilized with 0.2% 
(w/v) saponine, both in PBS, according to the 
protocol described earlier (26). Employed primary 
antibodies included anti-LAMP2 (2D5) (61), anti-
GM130 (BD Biosciences) and anti-PDI (Abcam) as 
well as the already mentioned anti-CD74, anti-βGal, 
anti-TNF Nterm and anti-HA. For visualization, 
Alexa-488 and -594 coupled secondary antibodies 
were utilized (MobiTec). After mounting in Mowiol 
supplemented with DABCO (1,4-diazobicyclo-(2.2.2) 
octane) and DAPI (4-,6-diamidino-2-phenylindole) 
photographs from optical sections were acquired 
with a FV1000 confocal laser scanning microscope 
(Olympus) equipped with an U Plan S Apo 64x oil 
immersion objective and Olympus Fluoview 




To evaluate potential transcriptional effects due to 
liberation of the overexpressed CD74 ICD, an 
exemplary microarray experiment was carried out 
using the CD74 ICD-TEV-GFPmem and CD74-ICD-
A7-GFPmem cell lines described above as well as a 
corresponding stably empty vector transfected cell 
line. In order to induce expression of the CD74 ICD 
fusion proteins, cells were treated for 24h with 
10 µg/ml doxycyclin (Sigma). Subsequently, RNA 
was isolated using the Nucleospin RNA® kit 
(Macherey Nagel). Genome wide transcriptome 
profiles were generated employing Human Gene 2.0 
ST Arrays (Affymetrix) according to the 
manufacturer's guidelines and further processed as 
previously described (62), while transcripts with a 




Generation of BMDCs 
SPPL2a- and CD74 deficient mice were described 
before (12,63) . For differentiation of bone marrow 
derived dendritic cells (BMDC) according to (64) the 
bone marrow of 3 animals per genotype was 
prepared by flushing tibia and femur bone marrow 
using 10 ml BMDC medium consisting of RPMI 
medium (GIBCO) supplied with 10% FBS, 100 U/ml 
penicillin, 100 µg/ml streptomycin and 50 µM β-
mercaptoethanol (GIBCO). 5x106 bone marrow cells 
were seeded in 10 cm dishes in 10 ml of RPMI 
medium supplied with 20 ng/ml GM-CSF 
(Immunotools). Fresh medium (10 ml) 
supplemented with the same amount of GM-CSF 
was added after 3 days. At day 6, 10 ml of medium 
were replaced by fresh BMDC medium containing 
10 ng/ml GM-CSF. At day 7, 1,5x106 cells were 




RNA was extracted using the Nucleospin RNA® kit 
according to the manufacturer’s recommendations. 
Afterwards, 1 µg RNA was transcribed into cDNA 
using the RevertAid First Strand cDNA Synthesis Kit 
(Thermo Scientific) in a 20 µl volume using random 
hexamer oligonucleotides. Finally 0.5 µl cDNA per 
reaction were analyzed via quantitative real-time 
PCR using the Universal Probe Library System 
(Roche) and a Lightcycler 480II (Roche). The 
following primers were used to determine 
expression of Secreted frizzled-related protein 2 
(SFRP2) and alpha tubulin for normalization: 
hSFRP2-fw, GCTAGCAGCGACC 
ACCTC; hSFRP2-rv, TTTTTGCAGGCTTCACATA 






Expression of murine and human SFRP2 was 
normalized to mTuba1a or hTuba1c, respectively. 
 
Statistical analysis 
Data shown represent means ± standard 
error of the mean (SEM). For statistical analyses, 
unpaired two-tailed t-test or one-way ANOVA 
followed by Tukey post hoc testing were used as 
indicated. Significance levels of p<0.05 (*), p<0.01 
(**) and p<0.001 (***) were applied. 
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Figure 1: Gal4/VP16 assays are not applicable to SPPL2a/b substrates. A) The 25 kDa Gal4/VP16 tag 
interferes with trafficking of murine TNF. For reporter assays based on Gal4/VP16 driven expression of a firefly 
luciferase a TNF construct was generated that harbored the Gal4/VP16 reporter at its N-terminus. HeLa cells 
seeded on coverslips were transiently transfected with HA-TNF-V5 or Gal4/VP16-TNF-V5 and the subcellular 
distribution of the TNF fusion proteins was analyzed by indirect immunofluorescence using an antibody against an 
N-terminal epitope of TNF. In parallel, endogenous GM130 was visualized. B) The Gal4/VP16-TNF fusion protein 
is not processed by SPPL2a. HeLa cells were transfected with either of the two TNF constructs alone or in 
combination with SPPL2a or the catalytically inactive SPPL2a D416A mutant (D/A). In order to inhibit endogenous 
SPPL2a, cells were treated for 6 h with the SPPL-inhibitor inhibitor X (1 µM) as indicated. Total cell lysates were 
analyzed by Western blotting with an antibody against an N-terminal epitope detecting the TNF full-length protein 
as well as different NTFs derived from the HA- and Gal4/VP16-tagged TNF. C) Transcriptional activation induced 
by the Gal4/VP16-TNF-V5 construct does not depend on SPPL protease activity. HeLa cells were transiently 
transfected with Gal4/VP16-TNF-V5, a response plasmid with a firefly luciferase under the control of a Gal4-
dependent promotor (pL8G5-Luc) and a constitutively expressed Renilla luciferase (pRL-TK). Cells were treated 
for 6 h with 1 µM inhibitor X and processed for determination of firefly and Renilla luciferase activities. The 
normalized ratio of firefly/renilla activities is shown. Bars indicate mean values of n=4 experiments ± SEM. One-
way ANOVA with Tukey post hoc testing was performed. ***P<0.001; ns, not significant. D) An N-terminal GFP-
tag disturbs subcellular trafficking of CD74. HeLa cells were transfected using CD74-HA or CD74 tagged with the 
24 kDa GFP-tag at its N-terminus (GFP-CD74) and subsequently analyzed for the distribution of the expressed 
proteins by indirect immunofluorescence using the In-1 antibody directed against the N-terminus of CD74. Co-
staining for endogenous PDI was performed. E) NTFs derived from GFP-tagged CD74 are not processed by 
SPPL2a. Processing of CD74-HA or GFP-CD74 was compared upon co-expression of both constructs with active 
or inactive (D/A) SPPL2a in transiently transfected HeLa cells. In B) and E) β-actin served as loading control. 
 
Figure 2: The βGal α-tag for βGEFC does not interfere with trafficking and processing of SPPL2a/b 
substrates. A) Design of the βGEFC-assay for quantitative detection of the CD74 ICD after its liberation by 
intramembrane proteolysis. In endosomes, proteolytic processing of CD74 generates an N-terminal fragment 
(NTF) that is subjected to SPPL2a intramembrane cleavage. In the assay, a CD74 fusion protein with the 
N-terminally appended βGal α-peptide is expressed in a reporter cell line that stably expresses the catalytically 
inactive βGal ω-fragment localized to the nucleus. After proteolytic release, the CD74 ICD is released to the 
cytosol and able to traffic to the nucleus thereby restoring βGal activity that serves as sensitive and quantitative 
readout. B) To test application of the small α-tag to the SPPL2a substrate CD74 two constructs were designed 
that differed in the presence or absence of an extrinsically added NLS between the βGal α-peptide and the CD74 
N-terminus. C) Endosomal/lysosomal targeting of CD74 was not impaired by the N-terminally appended 
α-peptide. The subcellular localization of α-CD74 and α-NLS-CD74 in comparison to CD74 devoid of any 
N-terminal tag was analyzed by immunofluorescence using the In-1 antibody in transiently transfected HeLa cells. 
Co-localization with the lysosomal/late endosomal protein LAMP-2 was determined with the 2D5 antibody. Scale 
bars = 10 µm. D) Processing of the different α-tagged CD74 reporter constructs by co-expressed active, but not 
inactive (D/A) SPPL2a was evaluated by Western blot analysis of transiently transfected HEK293 cells stably 
expressing the βGal ω-fragment in the nucleus (ωnuc cells) in comparison to CD74 without any N-terminal tag. E) 
Proteolytic cleavage of the α-tagged CD74 as expressed from the assay constructs by endogenous protease 
levels was validated by application of SPP/SPPL inhibitors to ωnuc cells transiently transfected with the indicated 
CD74 constructs. Cells were treated with inhibitor X (InX, 1 µM) or (Z-LL)2-ketone (ZLL, 20 µM) for 6 h prior to cell 
harvest. 
 
Figure 3: Establishment of a βGEFC assay to measure nuclear translocation. A) Design of a galactosidase 
based reporter construct. The ωnuc reporter construct is based on E. coli βGal with deletion of the α-peptide 
(aa 12-42) resulting in a catalytically inactive ω-fragment. Nuclear localization of the construct was enabled by 
addition of three SV40 nuclear localization sequences (NLS), a nuclear retention signal (NRS) from SC35 protein 
and a c-Myc-derived NLS. Nuclear transport of the reporter protein in a subcloned stable cell line was validated by 
indirect immunofluorescence analysis using an anti-βGal antibody. B) As a positive control with constitutive 
nuclear localization, an N-terminally α-tagged eGFP-construct was designed by fusing the βGal α-tag and three 
NLS to the 5’-end of the eGFP-coding sequence. Fluorescence microscopy showed distinct α-eGFPnuc 
expression in the nucleus in transiently transfected HeLa cells. C) As a negative control with a definite 
extranuclear localization, human TMEM192, an integral membrane protein of lysosomes with four transmembrane 
segments (TM), was tagged N-terminally with the βGal α-peptide and in addition with an HA epitope to enable 
detection. Presence of the fusion protein in lysosomes was validated in transiently transfected HeLa cells by 
indirect immunofluorescence by staining with the HA 3F10 antibody for TMEM192 and the 2D5 antibody for the 
lysosomal marker protein LAMP-2. Scale bars = 10 µm (A-C). D) Functionality of the assay was validated by 
expression of the positive and negative control constructs (B,C) in the ωnuc reporter cell line characterized in A) 
and quantification of βGal activity using a luminescent assay. The determined βGal signal was divided by the 




ratios were normalized to the value from the α-eGFPnuc positive control. Bars indicate mean values of n=3 
experiments ± SEM. One-way ANOVA with Tukey post hoc testing was performed. Significance versus vector-
transfected cells is depicted. ***P<0.001, ns, not significant. 
 
Figure 4: Nuclear translocation of the CD74 ICD can be detected by βGEFC and is dependent on SPPL2a 
activity. A) The α-CD74 ICD is capable of entering the nucleus as shown by βGEFC assay in the ωnuc reporter 
cell line. βGal activity was determined in ωnuc cells following transient transfection of α-CD74 and α-NLS-CD74 as 
well as the α-eGFPnuc positive and the α-TMEM192 negative controls. To account for differences in transfection 
activity, βGal activity was normalized using firefly luciferase (Luc). The calculated βGal/Luc ratios were further 
normalized to that of α-eGFPnuc positive control. Bars indicate mean values of n=3 experiments ± SEM. 
Significance of the CD74-expressing versus the α-TMEM192 transfected cells is depicted. B) Dependency of the 
determined βGal/Firefly Luciferase ratio on the amount of expressed CD74 was verified by transient transfection 
of different amounts of plasmids coding for α-tagged CD74. Mean values were calculated from n=3 experiments 
and error bars indicate SEM. C) Co-transfection of SPPL2a with α-CD74 increases the CD74-associated 
βGal/Luc activity ratio. Upon concurrent inhibition of SPPL2a activity by application of inhibitor X (InX, 1 µM, 6 h) 
this effect was abolished. Bars indicate mean values of n=3 experiments ± SEM. D) Inhibition of endogenous 
SPPL2a by inhibitor X (InX, 1 µM) or (Z-LL)2-ketone (ZLL, 20 µM) for 6 h reduced the CD74-associated βGal/Luc 
signal. A similar reduction of βGal complementation in ωnuc cells transiently transfected with α-CD74 was 
observed upon interference with the activity of proteases involved in processing of the CD74 luminal domain. This 
was performed by application of bafilomycin A1 (300 nM), E-64 (10 µM) or leupeptin (2.5 µM). Bars indicate mean 
values of n=3-7 experiments ± SEM. Significance of values from inhibitor-treated versus solvent-treated cells is 
depicted. E) Knock-down of SPPL2a in ωnuc reporter cells reduced the normalized βGal activity following 
expression of α-CD74. Cells were transfected twice with non-targeting control siRNA or siRNA directed against 
SPPL2a prior to transfection with the α-CD74 substrate construct. Reduction of cellular SPPL2a levels and an 
accumulation of the CD74 NTF were confirmed by Western blotting. Bars indicate mean values of n=3 
experiments ± SEM. For statistical analysis, one-way ANOVA with Tukey post hoc testing A,C,D) or an unpaired, 
two-tailed Student’s t test E) was performed. ***P<0.001, ** P<0.01, *P<0.05. 
 
Figure 5: The CD74 ICD is degraded by the proteasome and activates expression of SFRP2. A)  Incubation 
of α-CD74 transfected ωnuc cells with the proteasome inhibitors epoxomicin (1 µM) and bortezomib (5 µg/ml) 
clearly increased βGal complementation while application of a cytosolic peptidase inhibitor mix (Ama/Best/AAF) of 
amastatin (1 µM), bestatin (20 µM) and AAF-CMK (10 µM) had only minor effects. Bars indicate mean values of 
n=3 experiments ± SEM. B) The effect of epoxomicin shown in A), could be partially blocked by inhibition of 
SPPL2a by preincubation with inhibitor X (1 µM) respectively. Bars indicate mean values of n=4 experiments ± 
SEM. One-way ANOVA with Tukey post hoc testing was performed. C) Application of the proteasomal inhibitors 
epoxomicin and bortezomib only has minimal effects on the βGal ω-fragment. ωnuc cells were treated for 6 h with 
epoxomicin or bortezomib and subsequently analyzed for the stabilizing effect of these compounds on the 
reporter fragment by Western Blotting. β-actin served as loading control for normalization of densitometric 
quantification. D) Design of an inducible system for controlled overexpression of the CD74 ICD (aa 1-35). The 
ICD of CD74 was attached to a membrane anchored GFP by a TEV cleavage site or an uncleavable stretch of 
seven alanines (A7). Co-expression of a TEV protease via an IRES element only liberated the CD74 ICD in 
presence of the ENLYFQG cleavage site. The membrane-tethered cleavable (CD74-ICD-TEV-GFPmem) and non-
cleavable (CD74-ICD-A7-GFPmem) CD74-ICD-GFP fusion proteins were expressed from the depicted constructs 
that were used for the generation of stable FlipIn™T-Rex™293 cell lines. E) Characterization of the cell lines 
stably expressing CD74 ICD-TEV-GFPmem or CD74-ICD-A7-GFPmem upon induction with doxycyclin. FlipIn™T-
Rex™293 cell lines were generated based on the constructs shown in D) and treated with 10 µg/ml doxycyclin for 
24 h or left untreated. Expression of the fusion proteins was detected by Western blotting using anti-CD74 or anti-
GFP antibodies. The TEV protease was visualized with anti-Myc. F) SFRP2 is transcriptionally upregulated after 
overexpression and liberation of the CD74 ICD. The cell lines characterized in E) were treated for 24 h with 10 
µg/ml doxycyclin in order to induce expression of the CD74-ICD-GFP fusion proteins. Secreted frizzled-related 
protein 2 (SFRP2) expression was determined by qRT-PCR in both cell lines and normalized for expression of 
tubulin. Normalized SFRP2 transcript levels were significantly increased in the cell line expressing the cleavable 
CD74 ICD fusion protein (TEV) versus the control cell line (A7) where the ICD is not liberated. G) Sfrp2 is 
downregulated in SPPL2a and CD74 deficient BMDCs compared to wildtype cells. For statistical analysis, one-
way ANOVA with Tukey post hoc testing was performed. Significances in A) are depicted for inhibitor-treated 
versus solvent-treated cells. Also in B) significance of values from inhibitor-treated versus solvent-treated cells 
was depicted. Furthermore, significance of additional inhibitor X treatment in epoxomicin-treated cells was 
evaluated. In G) significances of SPPL2a or CD74 deficient versus wildtype BMDCs are indicated, lines mark 






Figure 6: SPPL2-dependent nuclear translocation of the TNF and ITM2B ICDs. A) To test further described 
SPPL2 substrates for nuclear translocation of their proteolytically liberated ICDs, assay constructs similar to those 
for CD74 were designed for TNF and ITM2B. In the ITM2B expression constructs also an HA-tag was added to 
allow antibody detection. B) The α-tag does not interfere with sorting of ITM2B and TNF. Comparison of HA-
tagged ITM2B and HA-TNF-V5 with the corresponding α-tagged fusion proteins by indirect immunofluorescence 
revealed no major differences regarding the subcellular distributions of the proteins in HeLa cells. Expression of 
ITM2B was determined using the HA 3F10 antibody while TNF localization was detected with a rabbit polyclonal 
against the N-terminus of the protein. Scale bars = 10 µm. C) βGEFC assays indicate nuclear translocation of 
TNF and ITM2B ICDs. Normalized βGal activity was determined in ωnuc reporter cells transiently expressing the 
indicated constructs. Bars indicate mean values of n=3 experiments ± SEM. D) Co-expression of active SPPL2a 
and SPPL2b enhanced the βGEFC assay signal in α-TNF expressing ωnuc reporter cells. This effect of co-
expressed SPPL2a/b was blocked by concurrent administration of inhibitor X (InX, 1 µM) for 6 h. Bars indicate 
mean values of n=4-5 experiments ± SEM. E) The assay signal induced by α-ITM2B could also be augmented by 
overexpression of SPPL2b and SPPL2a. Experiments were carried out in analogy to α-CD74 and α-TNF before. 
Bars indicate mean values of n=3 experiments ± SEM.One-way ANOVA with Tukey post hoc testing was 
performed. In A) significances versus the α-TMEM192 transfected cells were depicted. In D) and E) significances 
for the effect of the SPPL2a/b overexpression alone or in combination with inhibitor X application are shown. 
***P<0.001, *P<0.05, ns, not significant. 
 
Figure 7: The devised βGEFC assay is also applicable to other I-CLIPs like γ-Secretase. A) A Notch1 
reporter construct for the βGal assay was designed based on the Notch1ΔE construct which lacks the 
extracellular portion of the Notch1 receptor. Therefore, the resulting protein is constitutively processed by  
γ-secretase to generate the Notch1 ICD (NICD) for which nuclear translocation is well documented. The 
employed construct exhibited the βGal α-peptide and an additional HA-tag at its C-terminus. B) γ-secretase 
inhibition prevented generation and nuclear translocation of the NICD and stabilized the uncleaved NotchΔE-α 
protein at the plasma membrane. HeLa cells transiently expressing NotchΔE-α were treated with 1 µM DAPT for 
6 h and analyzed by indirect immunofluorescence using the HA 3F10 antibody. C) Application of the γ-secretase 
inhibitor DAPT, but not the SPP/SPPL inhibitor (Z-LL)2-ketone (ZLL) reduced the normalized βGal activity 
determined in the ωnuc reporter cell line following transient transfection of NotchΔE-α. Post transfection, cells were 
incubated overnight and subsequently treated with DAPT (1 µM), ZLL (20 µM) or DMSO as vehicle control for 6 h. 
Bars indicate mean values of n=3 independent experiments ± SEM. Scale bars = 10 µm. One-way ANOVA with 
Tukey post hoc testing was performed. Significance of values from NotchΔE-α expressing versus TMEM192 











Suppl. Table S1: Full list of putative CD74 ICD target genes. Microarray analysis of the inducible TREX CD74 
ICD-TEV-GFPmem and CD74-ICD-A7-GFPmem cell lines was performed. The relative abundance of transcripts was 
determined and the fold change (TEV/A7) was calculated. The table comprises all identified targets with a fold 
change > 2.0 or < -2.0. Protein-coding transcripts are marked in red. 
 
 
Suppl. Table S2: NFκB target genes are not differentially regulated by the liberated CD74 ICD. Gene 
expression profiles of the inducible TREX CD74 ICD-TEV-GFPmem and CD74-ICD-A7-GFPmem T-Rex™ were 
obtained by microarray analysis. The expression of documented NFκB target genes (http://www.bu.edu/nf-
kb/gene-resources/target-genes/) as well as genes associated to the NFKB-signaling pathway (KEGG hsa04064) 
was compared based on the calculated fold change (TEV/A7). No significant effect that would support a 
significant impact of the liberated CD74 ICD on the NFκB pathway in this cell system was observed. 
 
 
Suppl. Figure S1: Validation of transcriptional targets identified in the microarray experiment. The 
inducible TREX CD74 ICD-TEV-GFPmem and CD74-ICD-A7-GFPmem cell lines cell lines were treated for 24 h with 
10 µg/ml doxycyclin in order to induce expression of the CD74-ICD-GFP fusion proteins. Expression of TULP3, 
ZNF763, SFRP2, DHRSX, LUM, TPTE and CNTN1 was determined by qRT-PCR in both cell lines and 
normalized for expression of tubulin. The following primers in addition to those specified in the Materials & 
Methods section were used: hTULP3-fw, CCAGATAGTCCACAAAAATGACC; hTULP3-rv, 
GCCTGTACTGCACAAAGTGG; hZNF763-fw, GCTGTGCCCTTCTGTAGTCA; hZNF763-rv, 
CCACAGGGTCCTGAAACATC; hDHRSX-fw, CGGCTGGTTGCTTTTCAA; hDHRSX-rv, 
TCTCTTTCTCGTTGTATAGGTAATGG; hLUM-fw, GAAAGCAGTGTCAAGACAGTAAGG; hLUM-rv, 
GGCCACTGGTACCACCAA; hTPTE-fw, CCCCAGGCTCTTCTGACC; hTPTE-rv, 
AGAATCTGGTAGTGAATCCATAACTCT; hCNTN1-fw, GATGACTGGAAAGATGCAAAGA; hCNTN1-rv, 
CATGGGATTAAGTCCACTGCT. 
 
Item Associated with Significance for the paper 
Suppl. Table S1 Figure 5 Full list of differentially expressed genes from the microarray 
experiment, requested by reviewer 
Suppl. Table S2 Figure 5 List of NFκB target genes from the microarray dataset. The data 
exclude a major NFκB activation as a reason for the SFRP2 
upregulation by the CD74 ICD. A statement on this was requested 
by one of the reviewers. 
Suppl. Figure S1 Figure 5 Full experimental data on the validation of additional targets from 
the microarray experiments that were not followed up further, 
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ENLYFQG GFP IRES TEV Myc CD74 ICD (aa 1-35) STX7 (aa 229-261)
AAAAAAA GFP IRES TEV Myc CD74 ICD (aa 1-35) STX7 (aa 229-261)
CD74-ICD-TEV-GFPmem
CD74-ICD-A7-GFPmem
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Nuclear translocation after intramembrane cleavage
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